Neurocrine Biosciences (NBIX) PT Set at $100.00 by Oppenheimer

Oppenheimer set a $100.00 target price on Neurocrine Biosciences (NASDAQ:NBIX) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ FY2019 earnings at $1.47 EPS, FY2021 earnings at $7.71 EPS and FY2022 earnings at $8.57 EPS.

Several other equities analysts have also recently issued reports on NBIX. Deutsche Bank restated a buy rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. BidaskClub raised shares of Neurocrine Biosciences from a buy rating to a strong-buy rating in a research note on Wednesday, January 31st. Citigroup reaffirmed a buy rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Needham & Company LLC upped their price objective on shares of Neurocrine Biosciences to $95.00 and gave the company a buy rating in a research note on Tuesday, January 16th. Finally, Robert W. Baird reissued a buy rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $89.53.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up $1.69 during trading hours on Wednesday, hitting $85.38. 1,678,700 shares of the stock traded hands, compared to its average volume of 1,017,887. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a one year low of $39.21 and a one year high of $91.82.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million for the quarter, compared to the consensus estimate of $94.00 million. During the same period in the previous year, the firm earned ($0.51) EPS. research analysts expect that Neurocrine Biosciences will post 0.61 EPS for the current year.

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 6,279 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $75.04, for a total value of $471,176.16. Following the transaction, the insider now directly owns 19,436 shares of the company’s stock, valued at $1,458,477.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin Charles Gorman sold 105,983 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $80.25, for a total transaction of $8,505,135.75. Following the completion of the sale, the chief executive officer now owns 339,482 shares of the company’s stock, valued at approximately $27,243,430.50. The disclosure for this sale can be found here. Insiders sold 337,950 shares of company stock worth $26,613,876 over the last ninety days. Insiders own 4.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the last quarter. Crow Point Partners LLC purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $145,000. American International Group Inc. purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $161,000. M&T Bank Corp purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $202,000. Finally, Mission Wealth Management LP purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $204,000.

WARNING: “Neurocrine Biosciences (NBIX) PT Set at $100.00 by Oppenheimer” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2018/02/15/neurocrine-biosciences-nbix-pt-set-at-100-00-by-oppenheimer.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply